BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

The Jackson Laboratory Combines Food and Drug Discovery


7/25/2011 1:11:24 PM

July 25, 2011 -- The three-day conference, "Drug Discovery & Diagnostic Development Week" (http://www.ibclifesciences.com/DrugDisc/overview.xml), held August 1-3, in San Francisco, will be a tremendous opportunity for you to brush up on the latest drug discovery strategies. The Jackson Laboratory (JAX) has organized two special venues to enrich your conference experience:

On August 2, at 7:00 AM, at a special breakfast, Dr. Brandy Wilkinson, JAX® In Vivo Pharmacology Study Director, will give a presentation on the new JAX Cancer Consortium for Patient-Derived Xenografts (PDX). Developed in collaboration with UC Davis Cancer Center, Sacramento, CA, the Swedish Hospital, Seattle, WA, the Scripps Research Institute, La Jolla, CA, and UC San Diego Moores Cancer Center, the Consortium has created patient-derived xenograft models using NOD scid IL2 receptor gamma chain knockout (NSG) mice as hosts. Scientists will be able to use the models to support large-scale basic and preclinical cancer research.

On the same day, at 12:00 PM, at a special luncheon, a cadre of JAX scientists will facilitate round table discussions on three cutting-edge humanized mouse models: PDX, NSG, and FcRn. By overcoming species-specific differences between mice and humans, these models are more clinically relevant and more predictive of candidate drug efficacy than conventional models. JAX scientists will explain how these models can speed up drug discovery programs in antibody engineering, autoimmune diseases, hematopoiesis, infectious diseases, oncology, and other areas. To kick off the discussions, Yan Yang, Ph.D., head of JAX® In Vivo Pharmacology Services, will briefly highlight the models and introduce the subject matter experts. Leon Hall, Ph.D., JAX® In Vivo Pharmacology Program Director, will facilitate discussions on humanized NSG (hNSG) – immunodeficient NSG mice engrafted with a human immune system. Brandy Wilkinson, Ph.D., JAX® In Vivo Pharmacology Study Director, will facilitate discussions on PDX models – immunodeficient NSG mice engrafted with passaged human tumor tissues. And, Gabriele Proetzel, Ph.D., Associate Director of Technology Transfer at JAX, will facilitate discussions on humanized FcRn mice – mice that express human FcRn receptor to support human antibody PK studies.

Space for these events is limited. Register today at www.jax.org/jaxmice/events/2011/drugdiscovery-rsvp).



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->